{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:21:17Z","timestamp":1715955677487},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00393-018-0552-0","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T07:03:31Z","timestamp":1538377411000},"page":"881-888","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rituximab in routine care of\u00a0severe active rheumatoid arthritis"],"prefix":"10.1007","volume":"78","author":[{"given":"A.","family":"Krause","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. M.","family":"Aries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-M.","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"552_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13075-016-0951-z","volume":"18","author":"K Chatzidionysiou","year":"2016","unstructured":"Chatzidionysiou K, Lie E, Nasonov E et\u00a0al (2016) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther 18:50","journal-title":"Arthritis Res Ther"},{"key":"552_CR2","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/ard.2010.148759","volume":"70","author":"K Chatzidionysiou","year":"2011","unstructured":"Chatzidionysiou K, Lie E, Nasonov E et al (2011) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 70:1575\u20131580","journal-title":"Ann Rheum Dis"},{"key":"552_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/annrheumdis-2011-200003","volume":"71","author":"K Chatzidionysiou","year":"2012","unstructured":"Chatzidionysiou K, Lie E, Nasonov E et al (2012) Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a\u00a01-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 71:374\u2013377","journal-title":"Ann Rheum Dis"},{"key":"552_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","volume":"2","author":"MD Cohen","year":"2015","unstructured":"Cohen MD, Keystone E (2015) Rituximab for rheumatoid arthritis. Rheumatol Ther 2:99\u2013111","journal-title":"Rheumatol. Ther."},{"key":"552_CR5","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a\u00a0multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"552_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/acr.21865","volume":"65","author":"M Couderc","year":"2013","unstructured":"Couderc M, Mathieu S, Pereira B et\u00a0al (2013) Predictive factors of rituximab response in rheumatoid arthritis: results from a\u00a0French university hospital. Arthritis Care Res (Hoboken) 65:648\u2013652","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"552_CR7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a\u00a0randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 69:1629\u20131635 (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE))","journal-title":"Ann Rheum Dis"},{"key":"552_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Gottenberg JE, Rubbert-Roth A et al (2015) Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a\u00a0single previous TNF inhibitor: SWITCH-RA, a\u00a0global, observational, comparative effectiveness study. Ann Rheum Dis 74:979\u2013984","journal-title":"Ann Rheum Dis"},{"key":"552_CR9","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1093\/rheumatology\/ker253","volume":"50","author":"P Emery","year":"2011","unstructured":"Emery P, Mease PJ, Rubbert-Roth A et al (2011) Retreatment with rituximab based on a\u00a0treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a\u00a0retrospective pooled analysis. Rheumatology (Oxf) 50:2223\u20132232","journal-title":"Rheumatology (Oxf.)"},{"key":"552_CR10","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3899\/jrheum.141043","volume":"42","author":"LR Harrold","year":"2015","unstructured":"Harrold LR, Reed GW, Shewade A et al (2015) Effectiveness of Rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: results from the CORRONA Registry. J\u00a0Rheumatol 42:1090\u20131098","journal-title":"J Rheumatol"},{"key":"552_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","volume":"72","author":"JD Isaacs","year":"2013","unstructured":"Isaacs JD, Cohen SB, Emery P et al (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a\u00a0meta-analysis. Ann Rheum Dis 72:329\u2013336","journal-title":"Ann Rheum Dis"},{"key":"552_CR12","first-page":"191","volume":"6","author":"J Kekow","year":"2012","unstructured":"Kekow J, Mueller-Ladner U, Schulze-Koops H (2012) Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure. Biologics 6:191\u2013199","journal-title":"Biologics"},{"key":"552_CR13","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","volume":"48","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S et al (2009) Rheumatoid factor positivity rather than anti-CCP positivity, a\u00a0lower disability and a\u00a0lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxf) 48:1557\u20131559","journal-title":"Rheumatology (Oxf.)"},{"key":"552_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/annrheumdis-2015-207786","volume":"75","author":"A Richter","year":"2016","unstructured":"Richter A, Pattloch D, Manger B et\u00a0al (2016) Initiation of biologic treatment over the past 15 years reflects changes in treatment strategies: results from the prospective cohort of the German Biologics Register Rabbit. Ann Rheum Dis 75:874\u2013875","journal-title":"Ann Rheum Dis"},{"key":"552_CR15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/acr.22327","volume":"66","author":"A Richter","year":"2014","unstructured":"Richter A, Strangfeld A, Herzer P et al (2014) Sustainability of rituximab therapy in different treatment strategies: results of a\u00a03-year followup of a\u00a0German biologics register. Arthritis Care Res (Hoboken) 66:1627\u20131633","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"552_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"J Sellam","year":"2011","unstructured":"Sellam J, Hendel-Chavez H, Rouanet S et al (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a\u00a0six-month, national, multicenter, open-label study. Arthritis Rheum 63:933\u2013938","journal-title":"Arthritis Rheum"},{"key":"552_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/ard.2006.061002","volume":"66","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Keystone EC, Emery P et\u00a0al (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66:143\u2013150","journal-title":"Ann Rheum Dis"},{"key":"552_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jbspin.2011.05.002","volume":"79","author":"E Solau-Gervais","year":"2012","unstructured":"Solau-Gervais E, Prudhomme C, Philippe P et al (2012) Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 79:281\u2013284","journal-title":"Joint Bone Spine"},{"key":"552_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3899\/jrheum.110610","volume":"39","author":"MM Soliman","year":"2012","unstructured":"Soliman MM, Hyrich KL, Lunt M et\u00a0al (2012) Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J\u00a0Rheumatol 39:240\u2013246","journal-title":"J Rheumatol"},{"key":"552_CR20","first-page":"1695","volume":"60","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Eveslage M, Kekow J (2009) Effectiveness of treatment with rituximab depends on autoantibody status: results from 2 years of experience in the German biologics register RABBIT. Arthritis Rheum 60:1695 (Abstract)","journal-title":"Arthritis Rheum"},{"key":"552_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/03009740902946355","volume":"38","author":"H Valleala","year":"2009","unstructured":"Valleala H, Korpela M, Mottonen T et al (2009) Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scand J Rheumatol 38:323\u2013327","journal-title":"Scand J Rheumatol"},{"key":"552_CR22","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Vollenhoven Van","year":"2015","unstructured":"Van Vollenhoven RF, Fleischmann RM, Furst DE et\u00a0al (2015) Longterm safety of Rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J\u00a0Rheumatol 42:1761\u20131766","journal-title":"J Rheumatol"},{"key":"552_CR23","doi-asserted-by":"publisher","first-page":"R169","DOI":"10.1186\/ar3129","volume":"12","author":"B Vander Cruyssen","year":"2010","unstructured":"Vander Cruyssen B, Durez P, Westhovens R et\u00a0al (2010) The Belgian MIRA (MabThera In Rheumatoid Arthritis) Registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther 12:R169","journal-title":"Arthritis Res Ther"},{"key":"552_CR24","first-page":"893","volume":"34","author":"D Vassilopoulos","year":"2016","unstructured":"Vassilopoulos D, Delicha EM, Settas L et al (2016) Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a\u00a0long-term, prospective real-life study. Clin Exp Rheumatol 34:893\u2013900","journal-title":"Clin Exp Rheumatol"},{"key":"552_CR25","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/ar4521","volume":"16","author":"J Wendler","year":"2014","unstructured":"Wendler J, Burmester GR, Sorensen H et al (2014) Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a\u00a0prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther 16:R80","journal-title":"Arthritis Res Ther"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0552-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0552-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T12:05:45Z","timestamp":1572869145000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0552-0"}},"subtitle":["A\u00a0prospective, non-interventional study in\u00a0Germany"],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0552-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]},"assertion":[{"value":"1 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"A.\u00a0Krause: speakers\u2019 bureau for Abbvie, Berlin-Chemie, BMS, Celgene, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB; consultancy fees from Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi; research grants from Abbvie, Ovamed, Roche. P.M.\u00a0Aries: speakers\u2019 bureau for Abbvie, BMS, Celgene, Chugai, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Mundipharma, consultancy fees from Abbvie, Celgene, Lilly, Medac, Novartis, Pfizer, Roche, Sanofi; Chugai, Roche. C.\u00a0Fiehn: lecturer fees from Roche. H.-M.\u00a0Lorenz: consultancy\/lecturer fees, support for scientific projects, or travel reimbursements from Abbvie, Actelion, AstraZeneca, Bayer Vital, Baxter, Biogen, BMS, Celgene, Chugai, GSK, Janssen-Cilag, Lilly, Medac, MSD, Novartis, Octapharma, Pfizer, Roche, Shire, SOBI, UCB. L.\u00a0Meier: consultancy\/lecturer fees from Abbvie, BMS, Chugai-Roche, Lilly, Medac, MSD, Pfizer. U.\u00a0M\u00fcller-Ladner: consultancy\/lecturer fees from Roche, Chugai. A.\u00a0Schwarting: honoraria from GSK, research grants from AbbVie, BMS, Pfizer. H.-P.\u00a0Tony: consultancy\/lecturer fees from Abbvie, AstraZeneca, BMS, Chugai, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi. M.A.\u00a0Peters is an employee of Roche Pharma AG. J.\u00a0Wendler: consultancy\/lecturer fees from Roche. S.\u00a0Berger, H.\u00a0Kellner and G.A.\u00a0M\u00fcller declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}